Found 56 of ec50 data for polymerid = 4424,50006743 
Affinity DataEC50: 1.70nMAssay Description:Inhibition of OGA in rat PC12 cells assessed as OGlcNAcylated protein level incubated for 24 hrs by ELISAMore data for this Ligand-Target Pair
TargetProtein O-GlcNAcase(Homo sapiens (Human))
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:The ELISA portion of the assay is performed in a black Maxisorp 96-well plate that is coated overnight at 4° C. with 100 uL/well of the cell lysa...More data for this Ligand-Target Pair
TargetProtein O-GlcNAcase(Homo sapiens (Human))
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Affinity DataEC50: 4.70nMT: 2°CAssay Description:The ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4° C. with 100 μL/well of the cell l...More data for this Ligand-Target Pair
TargetProtein O-GlcNAcase(Homo sapiens (Human))
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Affinity DataEC50: 5.10nMT: 2°CAssay Description:The ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4° C. with 100 μL/well of the cell l...More data for this Ligand-Target Pair
TargetProtein O-GlcNAcase(Homo sapiens (Human))
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Affinity DataEC50: 5.20nMT: 2°CAssay Description:The ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4° C. with 100 μL/well of the cell l...More data for this Ligand-Target Pair
TargetProtein O-GlcNAcase(Homo sapiens (Human))
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Affinity DataEC50: 5.20nMAssay Description:Inhibition of O-GlcNAcase, which removes O-GlcNAc from cellular proteins, results in an increase in the level of O-GlcNAcylated protein in cells. An ...More data for this Ligand-Target Pair
TargetProtein O-GlcNAcase(Homo sapiens (Human))
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Affinity DataEC50: 6nMT: 2°CAssay Description:The ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4° C. with 100 uL/well of the cell ly...More data for this Ligand-Target Pair
TargetProtein O-GlcNAcase(Homo sapiens (Human))
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Affinity DataEC50: 8.80nMT: 2°CAssay Description:The ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4° C. with 100 μL/well of the cell l...More data for this Ligand-Target Pair
TargetProtein O-GlcNAcase(Homo sapiens (Human))
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Affinity DataEC50: 9.10nMAssay Description:Inhibition of O-GlcNAcase, which removes O-GlcNAc from cellular proteins, results in an increase in the level of O-GlcNAcylated protein in cells. An ...More data for this Ligand-Target Pair
TargetProtein O-GlcNAcase(Homo sapiens (Human))
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Affinity DataEC50: 10nMAssay Description:Inhibition of O-GlcNAcase, which removes O-GlcNAc from cellular proteins, results in an increase in the level of O-GlcNAcylated protein in cells. An ...More data for this Ligand-Target Pair
TargetProtein O-GlcNAcase(Homo sapiens (Human))
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Affinity DataEC50: 10nMT: 2°CAssay Description:The ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4° C. with 100 uL/well of the cell ly...More data for this Ligand-Target Pair
Affinity DataEC50: 11nMAssay Description:Inhibition of OGA in rat PC12 cells assessed as OGlcNAcylated protein level incubated for 24 hrs by ELISAMore data for this Ligand-Target Pair
TargetProtein O-GlcNAcase(Homo sapiens (Human))
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Affinity DataEC50: 13nMAssay Description:Inhibition of O-GlcNAcase, which removes O-GlcNAc from cellular proteins, results in an increase in the level of O-GlcNAcylated protein in cells. An ...More data for this Ligand-Target Pair
TargetProtein O-GlcNAcase(Homo sapiens (Human))
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Affinity DataEC50: 13nMT: 2°CAssay Description:The ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4° C. with 100 uL/well of the cell ly...More data for this Ligand-Target Pair
3D Structure (crystal)TargetProtein O-GlcNAcase(Homo sapiens (Human))
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Affinity DataEC50: 13nMAssay Description:Inhibition of O-GlcNAcase, which removes O-GlcNAc from cellular proteins, results in an increase in the level of O-GlcNAcylated protein in cells. An ...More data for this Ligand-Target Pair
TargetProtein O-GlcNAcase(Homo sapiens (Human))
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Affinity DataEC50: 13nMT: 2°CAssay Description:The ELISA portion of the assay is performed in a black Maxisorp 96-well plate that is coated overnight at 4° C. with 100 uL/well of the cell lysa...More data for this Ligand-Target Pair
Affinity DataEC50: 14nMAssay Description:Inhibition of OGA in rat PC12 cells assessed as OGlcNAcylated protein level incubated for 24 hrs by ELISAMore data for this Ligand-Target Pair
TargetProtein O-GlcNAcase(Homo sapiens (Human))
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Affinity DataEC50: 21nMAssay Description:Inhibition of OGA (unknown origin) by cell based assayMore data for this Ligand-Target Pair
Affinity DataEC50: 28nMAssay Description:Inhibition of OGA in rat PC12 cells assessed as OGlcNAcylated protein level incubated for 24 hrs by ELISAMore data for this Ligand-Target Pair
TargetProtein O-GlcNAcase(Homo sapiens (Human))
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Affinity DataEC50: 29nMT: 2°CAssay Description:The ELISA portion of the assay is performed in a black Maxisorp 96-well plate that is coated overnight at 4° C. with 100 uL/well of the cell lysa...More data for this Ligand-Target Pair
Affinity DataEC50: 30nMAssay Description:Inhibition of O-GlcNAcase in rat PC12 cells assessed as induction of OGlcNAcylation after 24 hrs by Western blot methodMore data for this Ligand-Target Pair
Affinity DataEC50: 31nMAssay Description:Inhibition of OGA in rat PC12 cells assessed as OGlcNAcylated protein level incubated for 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 33nMAssay Description:Inhibition of OGA in rat PC12 cells assessed as OGlcNAcylated protein level incubated for 24 hrs by ELISAMore data for this Ligand-Target Pair
TargetProtein O-GlcNAcase(Homo sapiens (Human))
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Affinity DataEC50: 34nMT: 2°CAssay Description:The ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4° C. with 100 uL/well of the cell ly...More data for this Ligand-Target Pair
Affinity DataEC50: 34nMAssay Description:Inhibition of OGA in rat PC12 cells assessed as OGlcNAcylated protein level incubated for 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 37nMAssay Description:Inhibition of OGA in rat PC12 cells assessed as OGlcNAcylated protein level incubated for 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 41nMAssay Description:Inhibition of OGA in rat PC12 cells assessed as OGlcNAcylated protein level incubated for 24 hrs by ELISAMore data for this Ligand-Target Pair
TargetProtein O-GlcNAcase(Homo sapiens (Human))
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Affinity DataEC50: 50nMAssay Description:Inhibition of O-GlcNAcase, which removes O-GlcNAc from cellular proteins, results in an increase in the level of O-GlcNAcylated protein in cells. An ...More data for this Ligand-Target Pair
TargetProtein O-GlcNAcase(Homo sapiens (Human))
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Affinity DataEC50: 53nMT: 2°CAssay Description:The ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4° C. with 100 uL/well of the cell ly...More data for this Ligand-Target Pair
Affinity DataEC50: 53nMAssay Description:Inhibition of OGA in rat PC12 cells assessed as OGlcNAcylated protein level incubated for 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 58nMAssay Description:Inhibition of OGA in rat PC12 cells assessed as OGlcNAcylated protein level incubated for 24 hrs by ELISAMore data for this Ligand-Target Pair
TargetProtein O-GlcNAcase(Homo sapiens (Human))
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Affinity DataEC50: 74nMAssay Description:Inhibition of O-GlcNAcase, which removes O-GlcNAc from cellular proteins, results in an increase in the level of O-GlcNAcylated protein in cells. An ...More data for this Ligand-Target Pair
Affinity DataEC50: 119nMAssay Description:Inhibition of OGA in rat PC12 cells assessed as OGlcNAcylated protein level incubated for 24 hrs by ELISAMore data for this Ligand-Target Pair
TargetProtein O-GlcNAcase(Homo sapiens (Human))
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Affinity DataEC50: 139nMT: 2°CAssay Description:The ELISA portion of the assay is performed in a black Maxisorp 96-well plate that is coated overnight at 4° C. with 100 uL/well of the cell lysa...More data for this Ligand-Target Pair
Affinity DataEC50: 152nMAssay Description:Inhibition of OGA in rat PC12 cells assessed as OGlcNAcylated protein level incubated for 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 165nMAssay Description:Inhibition of OGA in rat PC12 cells assessed as OGlcNAcylated protein level incubated for 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 176nMAssay Description:Inhibition of OGA in rat PC12 cells assessed as OGlcNAcylated protein level incubated for 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 177nMAssay Description:Inhibition of OGA in rat PC12 cells assessed as OGlcNAcylated protein level incubated for 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: <200nMAssay Description:Inhibition of OGA in rat B35 cells after 16 hrsMore data for this Ligand-Target Pair
Affinity DataEC50: 200nMAssay Description:Inhibition of OGA in rat B35 cells after 16 hrsMore data for this Ligand-Target Pair
Affinity DataEC50: 224nMAssay Description:Inhibition of OGA in rat PC12 cells assessed as OGlcNAcylated protein level incubated for 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 307nMAssay Description:Inhibition of OGA in rat PC12 cells assessed as OGlcNAcylated protein level incubated for 24 hrs by ELISAMore data for this Ligand-Target Pair
TargetProtein O-GlcNAcase(Homo sapiens (Human))
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Affinity DataEC50: 307nMT: 2°CAssay Description:The ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4° C. with 100 uL/well of the cell ly...More data for this Ligand-Target Pair
Affinity DataEC50: 328nMAssay Description:Inhibition of OGA in rat PC12 cells assessed as OGlcNAcylated protein level incubated for 24 hrs by ELISAMore data for this Ligand-Target Pair
TargetProtein O-GlcNAcase(Homo sapiens (Human))
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Affinity DataEC50: 349nMT: 2°CAssay Description:The ELISA portion of the assay is performed in a black Maxisorp 96-well plate that is coated overnight at 4° C. with 100 uL/well of the cell lysa...More data for this Ligand-Target Pair
TargetProtein O-GlcNAcase(Homo sapiens (Human))
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Affinity DataEC50: 358nMT: 2°CAssay Description:The ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4° C. with 100 uL/well of the cell ly...More data for this Ligand-Target Pair
Affinity DataEC50: 358nMAssay Description:Inhibition of OGA in rat PC12 cells assessed as OGlcNAcylated protein level incubated for 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 364nMAssay Description:Inhibition of OGA in rat PC12 cells assessed as OGlcNAcylated protein level incubated for 24 hrs by ELISAMore data for this Ligand-Target Pair
TargetProtein O-GlcNAcase(Homo sapiens (Human))
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Affinity DataEC50: 365nMT: 2°CAssay Description:The ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4° C. with 100 uL/well of the cell ly...More data for this Ligand-Target Pair
Affinity DataEC50: 443nMAssay Description:Inhibition of OGA in rat PC12 cells assessed as OGlcNAcylated protein level incubated for 24 hrs by ELISAMore data for this Ligand-Target Pair
